Recent Updates
Recently added Catalysts

Vasomotor Symptoms: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$3.5Buniverse median $1.20B
Allocated capital$3.5B$3.5B competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank55/299crowding rank 107

Vasomotor Symptoms is uncontested. AbCellera Biologics (ABCL) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with ABCL635 in phase 1.

There is no public comparable to price it against, and ABCL runs clinical programmes in this indication and nothing else, so its $3.5B market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$3.5B of allocated capital sits in Vasomotor Symptoms, ranking it 55th of 299 indications by the money committed to it.

Companies developing drugs for Vasomotor Symptoms 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ABCLAbCellera BiologicsABCL635Phase 11$3.5BYes1 30 Sep 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Vasomotor Symptoms counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Vasomotor Symptoms has one competitor and a median of $3.5B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Diabetes9 companies · $3.2B · median $401MKnife fightHypertriglyceridemia2 companies · $2.8B · median $10.9BConcentrated betChronic Heart Failure With Reduced Ejection Fraction1 company · $2.3B · median $9.2BUncontestedHeart Failure with Decompensation1 company · $2.3B · median $9.2BUncontestedCholestatic Liver Disease1 company · $2.2B · median $6.5BUncontestedATTR Amyloidosis2 companies · $2.0B · median $5.7BConcentrated betHypertrophic Cardiomyopathy4 companies · $5.2B · median $2.8BConcentrated betPostbariatric Hypoglycemia1 company · $1.9B · median $3.8BUncontested

Vasomotor Symptoms pipeline questions

Which biotech companies are developing drugs for Vasomotor Symptoms?

AbCellera Biologics (ABCL, ABCL635, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Vasomotor Symptoms.

How advanced is the Vasomotor Symptoms pipeline?

Of the 1 clinical-stage programme in Vasomotor Symptoms, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Vasomotor Symptoms?

No. ABCL is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Vasomotor Symptoms, which is why the indication is classified as uncontested.

When is the next Vasomotor Symptoms catalyst?

The next dated catalyst in Vasomotor Symptoms is ABCL on 30 Sep 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map